In recent trading session, Gossamer Bio Inc (NASDAQ:GOSS) saw 0.64 million shares changing hands at last check today with its beta currently measuring 1.93. Company’s recent per share price level of $1.43 trading at $0.01 or 1.06% at last check today assigns it a market valuation of $325.18M. That most recent trading price of GOSS’s stock is at a discount of -11.89% from its 52-week high price of $1.60 and is indicating a premium of 65.03% from its 52-week low price of $0.50.
For Gossamer Bio Inc (GOSS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.17 in the current quarter.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Upright in the green today for gaining 1.06%, in the last five days GOSS remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $1.43 price level, adding 4.67% to its value on the day. Gossamer Bio Inc’s shares saw a change of 58.63% in year-to-date performance and have moved 12.99% in past 5-day. Gossamer Bio Inc (NASDAQ:GOSS) showed a performance of 55.64% in past 30-days.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 64.25% to its recent value today. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -39.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -39.86% for stock’s current value.
Gossamer Bio Inc (GOSS) estimates and forecasts
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 7.02M for the same. And 6 analysts are in estimates of company making revenue of 3.48M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 11.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 76.06% while estimates for its earnings growth in next 5 years are of 26.42%.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
NEA MANAGEMENT COMPANY, LLC is the top institutional holder at GOSS for having 18.09 million shares of worth $16.3 million. And as of 2024-06-30, it was holding 7.9979 of the company’s outstanding shares.
The second largest institutional holder is ARTAL GROUP S.A., which was holding about 13.31 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.8832 of outstanding shares, having a total worth of $11.99 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 7.91 shares of worth $11.63 million or 3.49% of the total outstanding shares. The later fund manager was in possession of 7.84 shares on Sep 30, 2024, making its stake of worth around $11.52 million in the company or a holder of 3.46% of company’s stock.
